Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
Prostate Cancer Drug Helps Men Live Years Longer, New Data Shows
This post hoc analysis of a phase 3 randomized controlled trial in 1150 patients with metastatic hormone-sensitive prostate cancer found tha…
Men with advanced prostate cancer who took enzalutamide lived years longer than those on standard treatment alone, according to five-year da…
Time to biochemical progression predicts second events in high-risk prostate cancer
Longer time to progression predicts better outcomes in prostate cancer
This phase 3 RCT of 413 men with high-risk localized prostate cancer found that a longer time from randomization to biochemical progression …
Men with high-risk prostate cancer who had a longer time before their cancer worsened were less likely to have further progression or spread…
Darolutamide plus ADT delays pain progression in metastatic hormone-sensitive prostate cancer
New treatment delays pain in advanced prostate cancer
This randomised, double-blind, phase 3 trial in men with metastatic hormone-sensitive prostate cancer found that darolutamide plus androgen …
Men with advanced prostate cancer who took darolutamide stayed pain-free longer and felt better overall for months compared to those on stan…
Phase II trial of CyberKnife SBRT and androgen deprivation therapy in unfavorable intermediate- to high-risk localized prostate cancer
Small trial shows CyberKnife radiation plus hormone therapy is well tolerated for high-risk prostate cancer
This Phase II trial evaluated CyberKnife-based SBRT with simultaneous integrated boost and androgen deprivation therapy in 20 patients with …
A small study of 20 men with high-risk prostate cancer found that CyberKnife radiation plus hormone therapy was well tolerated with low rate…
MRI-RSI changes during neoadjuvant ADT and radiotherapy in men with high-risk localized prostate cancer
Early MRI scans shrink after treatment to help spot prostate cancer recurrence sooner
This prospective phase II trial protocol reports early results from 97 men with unfavorable-intermediate-risk or high-risk localized prostat…
New MRI scans taken before and during treatment for prostate cancer show clear shrinkage that could help doctors target the tumor more accur…
Systematic review finds neoadjuvant chemohormonal therapy improves biochemical progression-free survival in locally advanced prostate cancer
Chemo Before Prostate Surgery Linked to Better Cancer Control
This systematic review and meta-analysis evaluated neoadjuvant chemohormonal therapy (NCHT) combined with radical prostatectomy versus radic…
Patients with advanced prostate cancer may see better cancer control with chemo before surgery, though survival gains need more proof.
Expert panel agrees on early detection and ARPI/ADT role for high-risk prostate cancer BCR
Experts agree on some approaches for high-risk prostate cancer recurrence but disagree on timing
An expert opinion review summarized panel discussions on managing high-risk biochemical recurrence in prostate cancer.
Experts agree on early detection and medication use for high-risk prostate cancer recurrence but disagree on the best timing for starting tr…